RoslinCT and BlueRock Therapeutics Partner to Expand Access to Clinical-Grade Pluripotent Cell Lines for Cell Therapy Developers
RoslinCT, a leading global cell therapy Contract Development and Manufacturing Organization, today announced a strategic partnership with BlueRock Therapeutics, a leader in stem cell therapeutic development, to broaden access to clinical-grade pluripotent stem cell lines for cell therapy developers.
RoslinCT Announces Appointment of Jessica Carmen as Chief Commercial Officer
RoslinCT is pleased to announce the appointment of Jessica Carmen, Ph.D., to its global leadership team as Chief Commercial Officer. Dr. Carmen brings more than 20 years of experience in business development, licensing, and marketing roles in the cell and gene therapy industry, most recently serving as Vice President of Business Development at Kincell Bio.
RoslinCT Appoints Professor Sir Peter Mathieson and Alexander Vos as New Non-Executive Directors
RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, FRCPE, FMedSci, FRSE, FRSA and Alexander Vos as new Non-Executive Directors.
RoslinCT Boston Appoints Dean J. Morris, as Chief Operations Officer
RoslinCT, a leading contract development and manufacturing organization (CDMO) for Advanced Cell and Gene Therapies, is pleased to announce the appointment of Dean J. Morris as the Chief Operations Officer at their Boston facility. Mr. Morris brings a wealth of experience and expertise in commercial manufacturing operations, process development, engineering, validation, and quality functions within the biologics, pharmaceutical, and medical device industries.
RoslinCT Announces the Appointment of Dr. Derek Hei to its Scientific Advisory Board
RoslinCT, a leading contract development and manufacturing organization (CDMO) for Advanced Cell and Gene therapies, announced the appointment of Derek Hei, Ph.D., to its Scientific Advisory Board (SAB). The SAB is comprised of cell and gene therapy pioneers with extensive experience, providing valuable insight into a range of topics for the development and manufacturing of advanced therapies.
